PEB
20/05/2015 15:51
GENERAL
NOT PRICE SENSITIVE
REL: 1551 HRS Pacific Edge Limited
GENERAL: PEB: Full Year Results to be Released on 28 May 2015
20 May 2015
FULL YEAR RESULTS TO BE RELEASED ON 28 MAY 2015
Pacific Edge Limited (NZX:PEB) intends to announce its results for the
financial year ended 31 March 2015 on Thursday 28 May 2015, prior to 10am
NZST.
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage is a novel molecular test that combines the power of the
genomic biomarkers with extra phenotypic and clinical risk factors to
accurately identify and remove patients with hematuria who have a low
probability of bladder cancer, from needing to have a full-urological
work-up. This is a tool for use by clinicians and physicians in the primary
evaluation and is intended to reduce of the number of patients needing an
expensive and invasive work-up for urothelial cancer.
ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect is a proprietary, accurate molecular diagnostic test that
enables the non-invasive detection of bladder and other urinary tract cancers
from a small volume of urine. Cxbladder Detect is commercially available in
New Zealand, Australia and the USA. Cxbladder Detect is available in the USA
and NZ as a laboratory Developed Test (LDT) from the company's CLIA certified
laboratories, providing physicians and clinicians with a quick, cost
effective and accurate measure of the presence of the cancer, and provides
urologists with an effective adjunct to cystoscopy. The Cxbladder Detect
cancer detection test has been validated by a multicentre, international
clinical study.
ABOUT Bladder Cancer
Globally, bladder cancer has the 9th highest incidence and the 4th highest
incidence for men. One of the early symptoms of bladder cancer is the
presence of blood in the urine, haematuria. People with haematuria often
present to their general practitioner before being referred on to a
urologist. Bladder cancer has a very high recurrence rate of approximately
50%-70% with up to 30% of these recurring as later stage tumours. However,
bladder cancers are highly treatable, especially if detected in the early
stages when there is a much higher probability of survival. Timely detection
and regular surveillance and monitoring of this cancer is a key element of
the clinical process and of the individual's annual healthcare plan.
ABOUT Pacific Edge www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer. The
company is developing and commercialising its range of Cxbladder bladder
cancer tests. It's first commercial product, Cxbladder Detect, is now being
actively marketed to physicians and clinicians in New Zealand, Australia, and
the USA through the company's wholly owned subsidiaries and selected
commercial partners.
End CA:00264571 For:PEB Type:GENERAL Time:2015-05-20 15:51:52
